6533b7d2fe1ef96bd125ed8b
RESEARCH PRODUCT
Assessment of treatment response in hepatocellular carcinoma: a review of the literature
Santi Maurizio RaineriAntonello GiarratanoChiara GencoMassimo MidiriMarcello MaidaN. AlessiCalogero CammàRomano PClaudio GenovaGiuseppe BrancatelliGiuseppe Cabibbosubject
OncologyCancer ResearchTreatment responsemedicine.medical_specialtyCarcinoma HepatocellularLiver Function TestsInternal medicineClinical endpointHumansMedicineResponse criteriaNeoplasm StagingRandomized Controlled Trials as Topicbusiness.industrySurrogate endpointIncidence (epidemiology)Liver NeoplasmsGeneral MedicinePrognosismedicine.diseaseSurvival Analysisdigestive system diseasesRadiographyClinical PracticeTreatment OutcomeOncologyRadiological weaponHepatocellular carcinomabusinessdescription
Hepatocellular carcinoma (HCC) has a high incidence all over the world. Even if the primary end point of treatment of HCC is survival, radiological response could be a surrogate end point of survival, and could have a key role in clinical management. Since 1950 several radiological response criteria have been applied; however, it was not until 2000 that specific criteria for HCC were introduced by the European Association for the Study of the Liver (EASL), and these were then standardized in 2010 with the development of the modified Response Evaluation Criteria for Solid Tumors (mRECIST) for HCC. The purpose of this brief review is to compare data in literature regarding the application and the performance of mRECIST in clinical practice, and to discuss unclear and open issues.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2013-05-31 | Future Oncology |